Lab drug testing on tumor tissue to guide care for brain metastases
Tests pharmacoscopy-guided drug choice in adults with brain metastases needing surgery.
Key facts
- Who runs it
- University of Zurich
- Where
- Switzerland3 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Ex Vivo Drug Response Evaluation for Next Generation Care of Brain Metastases
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 102 people, planned
- Started
- 12 Sept 2025
- Expected to end
- Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Pharmacoscopy 1.0
- Control
- Record updated
- 29 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with probable brain metastases (cancer spread to the brain) who need surgery and have few drug treatment options left. It compares drug choice guided by testing tumor samples in the lab with standard care.
- Age
- 18 years or older
- Sex
- Female or male
- Disease stage
- Probable brain metastasis from any primary cancer, with a medical reason for surgery. The diagnosis must be confirmed on tissue taken during surgery. Karnofsky performance status of 60 or more (able to care for most personal needs). Several primary cancers are allowed.
- Earlier treatment
- Few drug treatment options must be left, as judged by the treating doctor. Any number of earlier treatment lines is allowed. People whose tumor has a targetable driver mutation must already have had a targeted drug, with those options used up.
Main reasons for not taking part
- Cancer elsewhere in the body that is getting worse quickly
- Unable to have a brain MRI
- Growing brain metastases that need radiotherapy to the whole brain after surgery
- Pregnant, planning pregnancy, or breastfeeding and not willing to stop
- Not willing to use effective birth control during the study
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Patients must be 18 years or older on the day of signing the informed consent, female or male
- Patients must have a Karnofsky performance status of 60 or more
- Patients must have limited systemic therapeutic options as per treating physician judgement. The number of previous lines of therapies is not limited
- Patients with a tumor with a targetable oncogenic driver mutation should have already been treated with a targeted agent and options must have been exhausted
- Patients must have a clinical indication for surgery for probable brain metastasis
- Patients will be considered eligible for the study only if the diagnosis of brain metastasis has been histologically confirmed on the sample obtained during the surgery performed after signing the informed consent form for the trial
- Any type of primary cancer is allowed: breast cancer, lung cancer, melanoma, other cancers. Patients may have several primary cancers
- Patients must have adequate bone marrow, renal and hepatic function documented at screening before surgery
- Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test
- Patients must have the ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments
- Written informed consent for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention
Who cannot take part
- Patients with progressive parenchymal brain metastases with an indication for requiring whole brain radiotherapy after surgery. Focal brain radiotherapy after surgery is allowed
- Female who are breastfeeding and who do not agree to discontinue nursing prior to the first treatment initiated during the study
- Patients with rapidly progressive systemic disease
- Patients with inability to undergo brain MRI evaluation
- Judgement by the investigator that the patient is unlikely to comply with study procedures, restrictions and requirements
- Intention to become pregnant during the course of the study
- Female who are pregnant
- Sexually active males and females of childbearing potential who are not willing to use an effective contraceptive method during the study. Male participants who do not agree not to donate sperm
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Pharmacoscopy refers to an ex vivo real-time drug sensitivity profiling platform that has been shown to be of value in the treatment of leukemia (Snijder et al. 2017) (Kornauth et al. 2022) and may help to identify novel treatment opportunities for brain tumors as well (Lee et al. 2022). The rationale for pharmacoscopy-based drug sensitivity testing on real-time patient biopsies or surgery material is multiple: measuring drug response and sensitivity directly in real-time patient material, overcomes the problem of limited molecular biomarkers for established targeted therapeutic options and can identify effective drugs even for non-targeted therapies such as chemotherapy. It can also identify hitherto unknown specific vulnerabilities of cancer cells. Furthermore, testing directly on patient material overcomes the limitations of patient-derived cell cultures, organoids, and patient xenografts, as their prolonged culture times risk cellular adaptations and clonal selection that alter drug sensitivity. Pharmacoscopy maintains the tumor cell composition, including bystander cells or tumor microenvironment, and limits cell culture to max 48 hours. Furthermore, pharmacoscopy measures drug responses on a single-cell and on a high-content level, uniquely allowing to measure the drug sensitivity of tumor cells, and allowing to compare it to the drug cytotoxicity on healthy cells from the same patient. This relative readout has previously been shown to be essential for the correct prediction of a clinical response in haematological malignancies (Snijder et al. 2017) (Kornauth et al. 2022).
Read full original descriptionShow less
The aim of this study is to generate preliminary data regarding superiority of the personalized pharmacoscopy-guided approach compared to a standard non-pharmacoscopy-guided approach, in patients with brain metastases with an indication for surgery, and limited therapeutic systemic options according to the treating physician.
The 2 groups in the trial
- Arm 1: experimental arm, Pharmacoscopy-guided treatmentTreatment being tested
Arm 1 (experimental arm): Pharmacoscopy-guided treatment will be prescribed by the investigator according to the results of the analysis (relevant on-target effect) and per drug prescription guidelines.
Treatment: Pharmacoscopy 1.0
- Arm 2: control armExisting treatment, for comparison
For patients randomized to the control arm, no pharmacoscopy analysis will be performed.
Treatment: Control
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Ex Vivo Drug Response Evaluation for Next Generation Care of Brain Metastases
- Plain-language title
- Lab drug testing on tumor tissue to guide care for brain metastasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 29 June 2026